Three months of liraglutide treatment significantly altered 151 plasma proteins in patients with obesity, reducing inflammatory markers while boosting metabolic and cellular repair proteins.
151 proteins significantly changedAfter just 3 months of liraglutide, the plasma protein landscape shifted dramatically — 120 proteins decreased (mostly inflammatory) and 31 increased (mostly metabolic), revealing the drug's broad molecular impact.
What the researchers found
Treatment with liraglutide 3 mg for three months significantly altered the plasma protein profile in patients with obesity. Of 151 dysregulated proteins, 31 were upregulated and 120 downregulated. Proteins involved in inflammation and oxidative stress were decreased, while those involved in glycolytic/lipolytic metabolism and cytoskeletal/endothelial reorganization increased. Top potential biomarkers (AUC 0.999) included upregulated Cystatin-B, major vault protein, and plastin-3, and downregulated multimerin-2, large ribosomal P2, and proline-rich acidic protein 1. Key affected pathways centered around MAPK, AKT, and PKc signaling.
Why it matters
While liraglutide's weight loss effects are well established, this study reveals the molecular machinery behind those benefits. The shift from inflammatory/oxidative stress proteins toward metabolic and cellular reorganization proteins provides a deeper understanding of how this GLP-1 peptide drug improves overall metabolic health beyond just appetite suppression and weight loss.
The numbers in context
n=20 · BMI 40.65 ± 3.7 kg/m² · 151 dysregulated proteins · 31 upregulated · 120 downregulated · top biomarkers AUC 0.999 · p<0.001 for weight, BMI, HbA1c changes · 3-month treatment
How the study worked
A single-center prospective study enrolled 20 patients with obesity (7 male, 13 female). Blood samples were collected before and after 3 months of liraglutide 3 mg treatment. Label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used for untargeted proteomic profiling. Differentially expressed proteins were identified and analyzed using bioinformatics, ROC curves for biomarker evaluation, and ingenuity pathway analysis (IPA) for network pathway identification.
Who was studied
20 adults (7 male, 13 female) with obesity, mean BMI 40.65 kg/m², mean age 36 years
What this study cannot tell us
The sample size of 20 patients is small, limiting generalizability. The study was single-center with no control group (before/after design only). Three months of treatment may not capture longer-term proteomic changes. The study measured plasma proteins, which may not fully reflect tissue-level molecular changes. Proteomic findings are exploratory and require validation in larger cohorts.
How to read the evidence
This is a prospective single-center study with a small sample size (n=20) and no control group. While the proteomic methodology is rigorous, the before/after design and limited sample size mean these findings are exploratory and require validation in larger, controlled studies.
When this study was published
Published in 2024, this study uses current proteomic technologies and reflects the growing interest in understanding the molecular mechanisms of GLP-1 receptor agonists beyond their weight loss effects.
The bigger picture
As GLP-1 receptor agonists become the most widely prescribed class of obesity medications, understanding their molecular effects beyond weight loss is crucial. This proteomic study suggests these peptide drugs may reduce cardiovascular and metabolic disease risk through direct anti-inflammatory and metabolic reprogramming effects, supporting the broader cardiovascular benefits seen in large outcome trials.
Questions still open
- Do the proteomic changes persist after liraglutide discontinuation, or do they revert along with weight regain?
- Are the same protein changes seen with other GLP-1 agonists like semaglutide, or are they specific to liraglutide?
- Could any of the identified biomarkers predict which patients will respond best to GLP-1 receptor agonist therapy?
Common questions
What does this proteomic study tell us that clinical trials don't?
Could the protein changes be due to weight loss rather than liraglutide itself?
Read the original research
Label-free quantitative proteomic profiling reveals differential plasma protein expression in patients with obesity after treatment with liraglutide.
Frontiers in molecular biosciences, 11, 1458675
Citation
Masood, Afshan; Benabdelkamel, Hicham; Joy, Salini Scaria; Alhossan, Abdulaziz; Alsuwayni, Bashayr; Abdeen, Ghalia; Aldhwayan, Madhawi; Alfadda, Nora A; Miras, Alexander Dimitri; Alfadda, Assim A. (2024). Label-free quantitative proteomic profiling reveals differential plasma protein expression in patients with obesity after treatment with liraglutide.. Frontiers in molecular biosciences, 11, 1458675. https://doi.org/10.3389/fmolb.2024.1458675